Centre de Recherche Hôpital Laval, Université Laval, Québec, Canada.
Nutr Metab (Lond). 2006 Feb 10;3:13. doi: 10.1186/1743-7075-3-13.
Thyroid abnormalities (hyperthyroid and hypothyroid) are accompanied by changes in intermediary metabolism including alterations in body weight, insulin resistance and lipid profile. The aims of this study were to examine plasma ASP, its precursor C3 and adiponectin in hyperthyroid and hypothyroid subjects as compared to controls.
A total of 99 subjects were recruited from endocrinology/out-patient clinics: 46 hyperthyroid subjects, 23 hypothyroid subjects and 30 control subjects. Subjects were evaluated for FT4, FT3, TSH, glucose, insulin, complete lipid profile and the adipokines: adiponectin, acylation stimulating protein (ASP) and complement C3.
Hyperthyroidism was associated with a 95% increase in adiponectin (p = 0.0002), a 47% decrease in C3 (p < 0.0001), no change in ASP and increased ASP/C3 ratio (p = 0.0012). Hypothyroidism was associated with a 31% increase in ASP (p = 0.008). Adiponectin and C3 correlated with FT3 (r = 0.383, p = 0.004 and r = -0.277, p = 0.007, respectively) and FT4 (r = 0.464, p = 0.003 and r = -0.225, p = 0.03, respectively). ASP correlated with TSH (r = 0.202, p = 0.04). Adiponectin did not correlate with either ASP or C3, only ASP and C3 correlated (r = -0.197, p = 0.05). Adiponectin was negatively correlated with BMI, total cholesterol and plasma triglyceride, while C3 was positively correlated with BMI and total cholesterol. Surprisingly, adiponectin was positively correlated with insulin (r = 0.293, p = 0.02) and HOMA-IR (r = 0.373, p = 0.003) while C3 was negatively correlated with glucose (r = -0.242, p = 0.022, insulin (r = -0.184, p = 0.05) and HOMA-IR.
These changes suggest that thyroid disease may be accompanied by changes in adipokines, which may contribute to the phenotype expressed.
甲状腺功能异常(甲亢和甲减)会导致中间代谢发生变化,包括体重、胰岛素抵抗和血脂谱的改变。本研究旨在比较甲亢和甲减患者与对照组之间血浆 ASP、其前体 C3 和脂联素的水平。
共招募了 99 名内分泌科/门诊患者:46 名甲亢患者、23 名甲减患者和 30 名对照组。对所有患者进行 FT4、FT3、TSH、血糖、胰岛素、完整血脂谱和脂联素、酰化刺激蛋白(ASP)和补体 C3 等脂肪因子的检测。
甲亢患者的脂联素水平升高了 95%(p=0.0002),C3 水平降低了 47%(p<0.0001),ASP 水平无变化,ASP/C3 比值升高(p=0.0012)。甲减患者的 ASP 水平升高了 31%(p=0.008)。脂联素和 C3 与 FT3(r=0.383,p=0.004 和 r=-0.277,p=0.007)和 FT4(r=0.464,p=0.003 和 r=-0.225,p=0.03)呈正相关。ASP 与 TSH 呈正相关(r=0.202,p=0.04)。脂联素与 ASP 或 C3 均无相关性,只有 ASP 和 C3 之间呈正相关(r=-0.197,p=0.05)。脂联素与 BMI、总胆固醇和血浆甘油三酯呈负相关,而 C3 与 BMI 和总胆固醇呈正相关。令人惊讶的是,脂联素与胰岛素(r=0.293,p=0.02)和 HOMA-IR(r=0.373,p=0.003)呈正相关,而 C3 与血糖(r=-0.242,p=0.022)、胰岛素(r=-0.184,p=0.05)和 HOMA-IR 呈负相关。
这些变化表明,甲状腺疾病可能伴随着脂肪因子的变化,这些变化可能导致表型的表达。